Characterization of Human Immune Signatures to Zoonotic Virus Exposure in Cambodia
- Conditions
- Immunity, Humoral
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 400
- Registration Number
- NCT06680843
- Locations
- π°π
Communicable Disease Control Department, Takeo, Cambodia
Safety and Immunogenicity of Stabilized CH505 TF chTrimer Vaccination in Adults Living With HIV-1 on Suppressive Antiretroviral Therapy
- Conditions
- HIV-1
- Interventions
- Biological: CH505 TF chTrimerOther: Sodium Chloride for InjectionBiological: 3M-052-AFBiological: Aluminum Hydroxide Suspension
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 30
- Registration Number
- NCT06680479
- Locations
- πΊπΈ
University of California, Los Angeles CARE Center CRS, Los Angeles, California, United States
πΊπΈUCSD Antiviral Research Center CRS, San Diego, California, United States
πΊπΈUniversity of California, San Francisco HIV/AIDS CRS, San Francisco, California, United States
Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in the HVTN706/MOSAICO Study and Remain Without HIV
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Target Recruit Count
- 40
- Registration Number
- NCT06665646
- Locations
- π΅πͺ
Lima - San Marcos, Bella Vista, Peru
π΅πͺIquitos (ACSA CRS), Iquitos, Peru
π΅πͺLima - Via Libre, Lima, Peru
Phase 1 Study of Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium Vivax Challenge Agent and Evaluate Transmission in Mosquito Feeding Assays
- Conditions
- Malaria
- Interventions
- Biological: P. vivax challenge agent derived from PvHMB-CCE001Biological: P. vivax challenge agent derived from PvHMB-CCE002
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2024-12-02
- Target Recruit Count
- 200
- Registration Number
- NCT06607003
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Study of a Human Bispecific Antibody VRC-HIVMAB0121-00-AB (CAP256J3LS) Administered Intravenously or Subcutaneously to Healthy Adults
- Conditions
- HIV Infection
- Interventions
- Biological: VRC-HIVMAB0121-00-AB
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-04
- Target Recruit Count
- 60
- Registration Number
- NCT06585891
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR
- Conditions
- Tenofovir
- Interventions
- Drug: Oral F/TDF PillsDrug: TFV rectal douche
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 150
- Registration Number
- NCT06560684
- Locations
- πΊπΈ
University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States
πΊπΈAlabama CRS (Site ID# 31788), Birmingham, Alabama, United States
πΊπΈUCLA CARE Center CRS, Los Angeles, California, United States
A Clinical Trial to Evaluate the Safety and Immunogenicity of CH505M5 N197D mRNA-gp160 Followed by CH505 TF mRNA-gp160 in Adults in Overall Good Health Without HIV
- Conditions
- HIV Infections
- Interventions
- Biological: CH505M5 N197D mRNA-gp160Biological: CH505 TF mRNA-gp160
- First Posted Date
- 2024-08-16
- Last Posted Date
- 2024-12-19
- Target Recruit Count
- 48
- Registration Number
- NCT06557785
- Locations
- πΊπΈ
Beth Israel Deaconess Medical Center (Site ID: 32077), Boston, Massachusetts, United States
πΊπΈColumbia P&S (Site ID: 30329), New York, New York, United States
πΊπΈNew York Blood Center (Site ID: 31801), New York, New York, United States
The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products
- Conditions
- Respiratory Syncytial Virus Infection
- Interventions
- Biological: AbrysvoBiological: Beyfortus
- First Posted Date
- 2024-08-13
- Last Posted Date
- 2025-01-03
- Target Recruit Count
- 200
- Registration Number
- NCT06551506
- Locations
- πΊπΈ
Emory University School of Medicine, Atlanta, Georgia, United States
πΊπΈUniversity of Maryland, School of Medicine, Center for Vaccine Development and Global Health, Baltimore, Maryland, United States
πΊπΈNew York University School of Medicine - Langone Medical Center - Vaccine Center, New York, New York, United States
Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age
- Conditions
- Human Parainfluenza Virus Type 3Human Metapneumovirus
- Interventions
- Biological: B/HPIV3/HMPV-PreF-A vaccineBiological: B/HPIV3/HMPV-F-B365 vaccineDrug: Placebo
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-12
- Target Recruit Count
- 25
- Registration Number
- NCT06546423
- Locations
- πΊπΈ
University of Rochester Medical Center, Rochester, New York, United States
πΊπΈCIR South, Columbia, Maryland, United States
πΊπΈVanderbilt University Medical Center, Nashville, Tennessee, United States
Safety and Pharmacokinetics Study of PGT121.414.LS Alone and in Combination With VRC07-523LS in Infants Exposed to HIV-1
- Conditions
- HIV-1
- Interventions
- Drug: PGT121.414.LSDrug: VRC07-523LS
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Target Recruit Count
- 48
- Registration Number
- NCT06517693
- Locations
- πΏπ¦
Site 8950, FAMCRU, Cape Town, Parrow Valley, South Africa
π΅π·Site 5129, IMPAACT/Gamma Project/UPR Pediatric HIV/AIDS Research, San Juan, Puerto Rico
πΊπΈSite 5092, Johns Hopkins University Baltimore, Baltimore, Maryland, United States